Liver Cancer News and Research

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Further Reading

Nitrogen is a basic building block of all the body's proteins, RNA and DNA, so cancerous tumors are greedy for this element. Researchers at the Weizmann Institute of Science, in collaboration with colleagues from the National Cancer Institute and elsewhere, have now shown that in many cancers, the patient's nitrogen metabolism is altered, producing detectable changes in the body fluids and contributing to the emergence of new mutations in cancerous tissue.

Johns Hopkins scientists report they have identified two potential new drug targets for the treatment of HIV. The finding is from results of a small, preliminary study of 19 people infected with both HIV-;the virus that causes AIDS-;and the hepatitis C virus.

A research team led by scientists from the Cancer Institute of Singapore at the National University of Singapore has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma or primary liver cancer.

Mice fed a fattening diet develop new liver circadian rhythms that impact the way fat is accumulated and simultaneously burned, according to a new study published in Cell by researchers in the Perelman School of Medicine at the University of Pennsylvania.

Nucleix Ltd., a leading cancer detection and screening company, announced today that the multi-center European study results with its Bladder EpiCheck urine test for the detection of bladder cancer recurrence, were published in the European Urology Oncology journal.

Analysis of cancer death data from 2008-2014 in New York state revealed high cancer mortality rates among U.S.-born blacks and Puerto Ricans and relatively low cancer mortality rates among Hispanic South Americans and Asians.

A new study by scientists from the Vrije Universiteit Brussel calls for a new gold standard in research to treat non-alcoholic steatohepatitis, an obesity-linked chronic liver disease impacting millions of people of all ages worldwide, which can progress to liver cancer if untreated, creating a massive strain on an already overburdened healthcare system.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, "A3 adenosine receptor ligands for use in treatment of a sexual dysfunction."

One of the lines of research of the UPV/EHU's Lipids & Liver group, which focusses on the mechanisms involved in the development and progression of non-alcoholic fatty liver disease, is achieving significant advances in a range of aspects; these include the identification of proteins that alter the metabolic pathways in the development and progression of liver disease, and even cancer, and the seeking of targets to enable the disease to be reversed.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that U.S. researchers published scientific findings recommending development of anti-Liver Cancer Drugs based on a mechanism of action utilized by Namodenoson.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial with drug candidate Namodenoson in the treatment of advanced hepatocellular carcinoma in patients whose disease has progressed on sorafenib therapy.

In this interview, Haiying Zhang, Assistant Professor of Cell and Development Biology from the Department of Pediatrics at Weill Cornell Medicine talks to News – Medical about the importance of Exosomes.

At St. John's, we are building an innovation center in pharmaceutical technology. We are involved with double upping new drug delivery systems, as well as a new processing agreement. In addition, we are focussing on personalized medications.

Other Useful Links

News-Medical.Net provides this medical information service in accordance
with these terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.

By continuing to browse or by clicking "Accept All Cookies," you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Find out more.